Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Recruiting

Phase 1

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Sponsor:

Tanja Andrea Gruber

Code:

NCT04996160

Conditions

Acute Lymphoblastic Leukemia, Pediatric

Relapsed Acute Lymphoblastic Leukemia

Refractory Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Interventions

Palbociclib

Dexamethasone

Bortezomib

Doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Tanja Andrea Gruber on 2025-03-25.